Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
Base Excision Repair01:54

Base Excision Repair

One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine Learning-Based Identification of Tamoxifen Resistance-Associated Genes and Their Application in Prognostic Modeling of Breast Cancer.

Journal of visualized experiments : JoVE·2026
Same author

Research Progress on DNA Damage Repair Efficiency Assessment Strategies.

Journal of visualized experiments : JoVE·2026
Same author

Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.

Nature cancer·2026
Same author

New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.

iScience·2026
Same author

The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.

Journal of visualized experiments : JoVE·2026
Same author

TIP-20, a novel feline McDonough sarcoma-like tyrosine kinase 3 inhibitor with potent antileukemia activity.

The Journal of international medical research·2026

Related Experiment Video

Updated: May 31, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer.

Yijie Wu1,2, Xiaoqiang Li3, Weijie Wang2

  • 1Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215009 Suzhou, Jiangsu, China.

Frontiers in Bioscience (Landmark Edition)
|May 30, 2026
PubMed
Summary

DNA damage repair (DDR) pathways are crucial in breast cancer drug resistance. Targeting these pathways offers personalized treatment strategies for doxorubicin-resistant tumors.

Keywords:
DNA repairbreast neoplasmsdoxorubicindrug resistancemolecular targeted therapyneoplasm

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Related Experiment Videos

Last Updated: May 31, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer remains a leading cause of cancer mortality in women, with significant heterogeneity.
  • Acquired resistance to chemotherapy, such as doxorubicin (DOX), is a major clinical challenge.
  • DNA damage repair (DDR) pathways play a critical role in the efficacy of chemotherapy and the development of drug resistance.

Purpose of the Study:

  • To review the role of five major DNA repair pathways in doxorubicin (DOX) resistance in breast cancer.
  • To provide a theoretical framework for understanding DDR mechanisms in DOX-resistant breast cancer.
  • To guide future research and advance intervention strategies for resistant breast tumors.

Main Methods:

  • Literature review focusing on the involvement of homologous recombination, nonhomologous end-joining, base excision repair, nucleotide excision repair, and mismatch repair.
  • Analysis of the impact of these DDR pathways on doxorubicin (DOX) efficacy and resistance.
  • Synthesis of current knowledge to establish a framework for future studies.

Main Results:

  • Five major DNA repair pathways (homologous recombination, nonhomologous end-joining, base excision repair, nucleotide excision repair, and mismatch repair) are identified as key players in the development of DOX resistance.
  • Understanding the specific roles of these pathways can elucidate mechanisms of resistance.
  • Deficiencies in specific DDR pathways may present opportunities for targeted therapies.

Conclusions:

  • DNA damage repair (DDR) pathways are pivotal in mediating breast cancer resistance to doxorubicin (DOX).
  • Targeting specific DDR mechanisms in patients with defined repair deficiencies holds promise for personalized therapeutic approaches.
  • This review provides a foundation for further research into DDR in DOX-resistant breast cancer, aiming to improve treatment outcomes.